What is Genascence?
Genascence is a biotechnology company founded in 2017 and based in California. It is dedicated to revolutionizing the treatment of prevalent musculoskeletal diseases through advanced gene therapy. The company's pipeline targets highly prevalent conditions, aiming to deliver life-changing therapies to a broad patient population. This focus positions Genascence at the forefront of innovation in regenerative medicine and genetic therapeutics.
How much funding has Genascence raised?
Genascence has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2022): $10.5M with participation from Pacira BioSciences
Key Investors in Genascence
Pacira BioSciences
Pacira BioSciences Inc. is a company operating within the Physicians Clinics industry, indicating a potential focus on therapeutic applications and patient care pathways relevant to Genascence's gene therapy treatments.
What's next for Genascence?
The recent major strategic investment signals a pivotal growth phase for Genascence. This capital infusion is expected to accelerate the company's development pipeline, potentially advancing its gene therapy candidates through critical clinical trials. The enterprise-level funding context suggests a strategic focus on scaling operations, expanding research capabilities, and preparing for future commercialization efforts. Genascence is poised to make significant strides in addressing unmet medical needs in the musculoskeletal disease space.
See full Genascence company page
